港股異動 | 康希諾生物-B飆升近11% 擬於A股配發不超2480萬股及申請科創板上市
格隆匯10月14日丨希諾生物-B(06185.HK)今日股價高開高走,現大漲10.71%,報38.75港元,暫成交820.9萬港元,最新總市值86.3億港元。

康希諾生物-B(06185.HK)公佈,該公司建議向中國相關監管機構申請配發及發行不多於2480萬股A股,以及建議向上海證券交易所申請批准A股在上交所科創板上市及買賣。
公司H股於2019年3月上市後,A股發行使公司能夠進一步豐富其資本基礎、優化公司治理結構及開發國內外融資平台。
此外,在A股上市將使該公司能夠進一步提升其品牌形象及在國內市場的影響力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.